Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data

Abstract

BackgroundErythropoiesis-stimulating agents (ESAs) reduce anemia in cancer patients and may improve quality of life, but there are concerns that ESAs might increase mortality. ObjectivesOur objectives were to examine the effect of ESAs and identify factors that modify the effects of ESAs on overall survival, progression free survival, thromboembolic and cardiovascular events as well as need for transfusions and other important safety and efficacy outcomes in cancer patients. Search strategyWe searched the Cochrane Library, Medline, Embase and conference proceedings for eligible trials.Manufacturers of ESAs were contacted to identify additional trials. Selection criteria1 Erythropoietin or Darbepoetin for patients with cancer -meta-analysis based on individual patient data (Review) Copyright © 2009 The Cochrane Collaboration.Published by

Ähnliche Arbeiten